| 1/5 | US=94 / Biol/Mol Matthews DJ, Gerritsen ME. Receptor tyrosine kinases. In: ___. Targeting protein kinases for cancer therapy. New Jersey: Wiley, 2010. p. 119-213. ISBN 978-0-470-22965-1. RECEPTORES DA TIROSINA QUINASE (RTK); FATOR DE CRESCIMENTO EPIDERMICO; CANCER; FATOR DE CRESCIMENTO INSULIN-LIKE (IGF); QUINASE DO LINFOMA ANAPLASICO (ALK); FATOR DE CRESCIMENTO VASCULAR ENDOTELIAL (VEGF); FATOR DE CRESCIMENTO DERIVADO DE PLAQUETAS (PDGF); TUMORES ESTROMAIS GASTROINTESTINAIS; SINDROME HIPEREOSINOFILICA; GLIOBLASTOMA; TUMOR MALIGNO DA BAINHA DE NERVO PERIFERICO; EOSINOFILIA; DERMATOFIBROSARCOMA PROTUBERANS; PERICITO; FATOR DE CRESCIMENTO FIBROBLASTICO; KIT; MASTOCITOSE; CANCER DE PULMAO DE PEQUENAS CELULAS; MELANOMA; LEUCEMIA MIELOIDE AGUDA; LINFOMA NASOSSINUSAL; TUMORES TESTICULARES DE CELULAS GERMINATIVAS; FLT3; LEUCEMIA; RET; CARCINOMA DE TIREOIDE; MET; RON |
| 2/5 | US=94 / Biol/Mol Matthews DJ, Gerritsen ME. Tyrosine kinase inhibitors. In: ___. Targeting protein kinases for cancer therapy. New Jersey: Wiley, 2010. p. 435-525. ISBN 978-0-470-22965-1. INIBIDORES DA TIROSINA QUINASE; INIBIDOR BCR-ABL; INIBIDORES SRC; INIBIDORES JAK2; INIBIDORES EGFR; INIBIDORES IGF1R; INIBIDORES FLT3; INIBIDORES KIT; INIBIDORES MET/RON; INIBIDORES RET; INIBIDORES FAK; INIBIDOR TGFB |
| 3/5 | US=35 / Câncer Mesa RA, Kaufmann SH. Molecular foundations of AML pathogenesis and physiology: altered apoptosis in AML. In: Karp JE. Acute myelogenous leukemia. New Jersey: Humana Press, 2007. p. 133-61. ISBN 978-1-58829-621-4. LEUCEMIA MIELOGENA AGUDA; APOPTOSE; RESISTENCIA MEDICAMENTOSA; BCL-2; MCL-1; XIAP; MICROAMBIENTE DA MEDULA OSSEA; RAS; FLT3 |
| 4/5 | US=35 / Câncer Levis M. Molecular therapeutics of AML: FLT3: a prototype receptor tyrosine kinase target in AML. In: Karp JE. Acute myelogenous leukemia. New Jersey: Humana Press, 2007. p. 247-61. (Contemporary Hematology) ISBN 978-1-58829-621-4. LEUCEMIA MIELOIDE AGUDA; QUINASE; FLT3; PROGNOSTICO; INIBIDORES; CELULAS TRONCO |
| 5/5 | US=92 / Biol/Mol Deininger M. Established cancer therapies: tyrosine kinase inhibitors. In: Gewirtz DA, Holt SE, Grant S. Apoptosis, senescence and cancer. 2 ed. New Jersey: Humana Press, 2007. p. 477-508. (Cancer Drug Discovery and Development) ISBN 978-1-58829-527-9. TERAPIA-ALVO; BCR-ABL; FLT3; EGFR; TYROSISE INIBITORS QUINASE; IMATINIB; GEFITINIB; ERLOTINIB; CANCER; LEUCEMIA |